Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

Reference number 8377, 8717, 10459, 10460

Sectors: Pharmaceuticals

Industries: Cardiovascular

A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity

Proposed use

Anthracycline chemotherapy leads to acute cardiotoxicity in up to 30% of patients. The MAP4K4 inhibitors can be commercialized to be used for protective agents against anthracycline therapy-induced cardiotoxicity.

Additionally, MAP4K4 is a pivotal mediator of a number of key pathways and a target in a range of clinical applications with significant unmet need. These targets include:

  • Neurodegeneration
  • Vascular disease
  • Cancer (including glioblastoma)
  • Anti-tumour and antiviral immunity
  • Autoimmune disorders including diabetes

Technology overview

  • Novel, potent, highly-selective, non-toxic inhibitors
  • Protection against anthracycline therapy validated in human and rat cardiomyocytes.
  • Good inhibitors of MAP4K4 with DMPK work undertaken
  • Range of assays focused on developing highly-specific MAP4K4 inhibitor targeting ATP-binding pocket
  • Multiple screen cascade/in vivo and in vitro validation of target and pre-lead candidates
  • Encouraging safety profile with no adverse effect on cloned human channels
  • Growing excitement in targeting MAP4K4 for other clinical applications


  • The compounds inhibit MAP4K4 in the low-mid nanomolar range
  • Pre-clinically validated protection against anthracycline cardiotoxicity
  • Demonstrated safety in murine and porcine models
  • MAP4K4 an attractive target in other indications

Intellectual property information

This technology is protected by a family of patents covering composition of matter and use  of two distinct chemical series number WO2018035563A1 and number WO2019073253A1.


Professor Michael Schneider

Chair in Cardiology
Faculty of Medicine, National Heart & Lung Institute

Visit personal site

Contact us about this technology

8377 - contact


Stephanie Morris

Director of Industry Partnerships and Commercialisation, Medicine

Stephanie Morris is Director of Industry Partnerships and Commercialisation for the Faculty of Medicine at Imperial College London.

Contact Stephanie

+44 (0)20 7594 2717

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.